geniposide has been researched along with Parkinson Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, X; Cao, P; Chen, B; He, Z; Qin, Y; Shen, J; Wang, Y; Xu, Y; Yang, Y; Ye, J; Zhou, Q | 1 |
| Chen, H; Deng, M; Li, X; Liu, K; Shi, M; Xie, L; Zhang, X | 1 |
| Chen, Y; Hölscher, C; Li, L; Zhang, Y | 1 |
| Lou, J; Su, C; Yang, X | 1 |
1 review(s) available for geniposide and Parkinson Disease
| Article | Year |
|---|---|
Therapeutic potential of catalpol and geniposide in Alzheimer's and Parkinson's diseases: A snapshot of their underlying mechanisms.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Drugs, Chinese Herbal; Gardenia; Humans; Iridoid Glucosides; Iridoids; Medicine, Chinese Traditional; Parkinson Disease; Rehmannia | 2021 |
3 other study(ies) available for geniposide and Parkinson Disease
| Article | Year |
|---|---|
Geniposide protects against neurotoxicity in mouse models of rotenone-induced Parkinson's disease involving the mTOR and Nrf2 pathways.
Topics: Animals; Chromatography, Liquid; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Neurotoxicity Syndromes; NF-E2-Related Factor 2; Oxidative Stress; Parkinson Disease; Rotenone; Tandem Mass Spectrometry; TOR Serine-Threonine Kinases | 2024 |
Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Proliferation; Disease Models, Animal; Iridoids; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neurons; Neuroprotective Agents; Parkinson Disease; Pars Compacta; Proto-Oncogene Proteins c-bcl-2; Psychomotor Performance; Swimming; Tyrosine 3-Monooxygenase | 2015 |
Geniposide reduces α-synuclein by blocking microRNA-21/lysosome-associated membrane protein 2A interaction in Parkinson disease models.
Topics: alpha-Synuclein; Animals; Cell Line, Tumor; Disease Models, Animal; Dopaminergic Neurons; Humans; Iridoids; Lysosomal-Associated Membrane Protein 2; Mice; MicroRNAs; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase | 2016 |